EANS-News: Balda AG / Medical subsidiary obtains regulatory approval for an innovative product under its own name for the first time

Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.

Bad Oeynhausen (euro adhoc) – Balda AG: Medical subsidiary obtains regulatory
approval for an innovative product under its own name for the first time

Successful system integration of hardware and software for a unique
pharmaceutical dispenser

Bad Oeynhausen, 6 October 2010 – Balda Medical GmbH & Co. KG, Bad Oeynhausen, an
affiliated company of Balda AG listed on the SDax on the Frankfurt Stock
Exchange, has successfully completed the development of an innovative product on
behalf of a global pharmaceutical client. ‘The device supports the effect of the
medicine by timely, precise and regular use. This unique pharmaceutical
dispenser combines both mechanical components and electronic assistance systems
in one. We are responsible for both, the complete implementation of hardware as
well as software’, explains Dr. Rolf Eilers, CEO of Balda Medical. In addition,
the company satisfies all regulatory requirements. Balda Medical has obtained
the regulatory approval for the pharmaceutical dispenser under its own name for
the first time for the European market (CE-symbol). The core business of the
company, based in Bad Oeynhausen, comprises the development, the set up for mass
production and the production of disposable articles as well as complex products
manufactured from plastic. The main customer base comes from the
pharmaceuticals, diagnostics and medical technology market segments.

The product, which is also intended for the U.S. market, was developed in
accordance with the requirements of the U.S. Food and Drug Administration (FDA).
Balda Medical will provide comprehensive product documentation for the approval
procedure, called ‘Device Master File’. The company has been registered as a
manufacturer by the FDA since 2009.

With the new drug dispenser Balda Medical is following important market trends
in two ways. The rapidly increasing self-care of patients with hand-held devices
occurs more frequently now using electronic support. The appropriate and
controlled intake of medicine allows for a significantly improved treatment of

The successful system integration of software and hardware, as well as the lead
responsibility for regulatory requirements, demonstrates the broad service
portfolio and the competitive strengths of the system partner Balda Medical.
‘The demand from our customers for a variety of capabilities from one source is
constantly increasing,’ said Eilers.

* * *
Company Profile Balda AG
The Balda Group develops and produces complete plastic assemblies, electronic
products and products for the medical industry. The customers of Balda are
leaders in business from the mobile, entertainment and electronic communications
as well as pharmaceutical and medical technology markets. The group has an
international position with product sites in China, Malaysia and Germany. A
subsidiary in the United States serves North American customers in product
design and development. As part of a shareholding in a leading manufacturer of
touch screens in China, Balda participates in the dynamic touch screen displays

* * *

This corporate news announcement includes ‘forward-looking statements’ which are
based on the current expectations of the management of Balda. They are subject
to risks and uncertainty because they relate to events and depend on
circumstances that will occur in the future, such as, for example, developments
in the mobile communications industry, changes in technology and the ability to
timely and successfully develop new products and various other factors. Balda
does not undertake any obligation to update publicly or revise forward-looking
statements except to the extent legally required. This corporate news
announcement is not an offer of securities for sale or a solicitation of an
offer to purchase securities in the United States or elsewhere. The shares in
Balda AG (the ‘Shares’) may not be offered or sold in the United States or to or
for the account or benefit of U.S. persons (as such term is defined in
Regulation S under the U.S. Securities Act of 1933, as amended (the ‘Securities
Act’) unless registered under the Securities Act or pursuant to an exemption
from such registration. The Shares have not been and will not be registered
under the Securities Act.

Further inquiry note:
Clas Röhl
Tel.: +49 (0) 5734 922-2728

company: Balda AG
Bergkirchener Str. 228
D-32549 Bad Oeynhausen
phone: +49 (0) 5734 9 22-0
FAX: +49 (0) 5734 922-2747
mail: info@balda.de
WWW: ¿U1http://www.balda.de¿U0
sector: Semiconductors & active components
ISIN: DE0005215107
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, München
language: English